Salubris Biotherapeutics

CompanyUnited States

Salubris Biotherapeutics develops 2 assets, the furthest in phase 2 (JK06 in breast cancer). Mostly other and protein or enzyme; based in the United States.

2
Assets
Furthest stage
Phase 2
6
Trials
0
Signals

Pipeline

2
  • JK06

    Targets 5T4-expressing tumor cells to deliver a cytotoxic drug payload.

    Phase 2, Other, breast cancer, locally advanced or metastatic solid tumors

  • JK07

    Neuregulin fusion protein selectively activates ERBB4 while blocking ERBB3, promoting cardiac repair and function.

    Phase 2, Protein or enzyme, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials6
  • Similar companies6

Intelligence